Detalhe da pesquisa
1.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268449
2.
A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Hematol Oncol
; 42(3): e3274, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38711253
3.
Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Cancer
; 124(15): 3192-3200, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29797667
4.
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Blood Cancer J
; 13(1): 147, 2023 09 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37726298
5.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Lancet Haematol
; 10(1): e35-e45, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36400069
6.
Temporal evolution of patient characteristics enrolled on phase I trials.
Invest New Drugs
; 29(2): 312-5, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19997961
7.
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors.
Invest New Drugs
; 29(1): 126-30, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19774342
8.
Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.
Br J Haematol
; 170(5): 734-6, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25716177
9.
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Clin Lymphoma Myeloma Leuk
; 20(11): e910-e925, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32912820
10.
Cocaine-induced thrombotic vasculopathy.
Am J Med Sci
; 342(6): 524-6, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21817879
11.
Multi-institutional phase I trials of anticancer agents.
J Clin Oncol
; 26(12): 1926-31, 2008 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18421046